Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus

Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.

Commercial Clinical Trials Companies

US FDA Opens Door For J&J's Spravato To Another MDD Population

The US FDA approved the esketamine nasal spray for adults with major depressive disorder with suicidal ideation or behavior, following its initial approval in 2019 for treatment-resistant depression. 

Neurology Launches Approvals

CymaBay’s Stalled Seladelpar Back In Play For PBC

Weeks after lifting of an FDA clinical hold, CymaBay says it will resume development of its PPAR agonist in primary biliary cholangitis. It will initiate a new Phase III trial but also use data from a terminated Phase III study.

Clinical Trials Drug Approval Standards Business Strategies


Recent Tweets from Scrip


Coronavirus 2019-nCov novel coronavirus concept resposible for asian flu outbreak and coronaviruses influenza as dangerous flu strain cases as a pandemic 3d rendering

COVID-19 Pipeline Tracker

Product candidates in development worldwide to address the 2019-nCoV pandemic, categorized by treatment and prevention. Subscription required.

View Tracker

 

Infographics

The 2020 Worldwide Pharma & Biotech Industry R&D Scene

INFOGRAPHIC: A snapshot of the industry in key performance indicators, taken in early 2020.

COVID-19: The Race To Develop A Vaccine

The world is waiting for a coronavirus vaccine – but can we depend on it, and when will it arrive? A visual tracker of key developments from leading candidates.

Titans Of Pharma 2020: A Bumper Year For Top Executive Compensation

INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.

Commercial Explore this Topic

Set Alert for Commercial

Top-Level Churn At Cipla's India Business

A Cipla veteran and CEO of the firm’s India business and other executives have quit, though the Indian company maintains it has underlying strength and continued business momentum to sustain growth. ANI Pharmaceuticals in the US has snapped up one outgoing executive as president and CEO.

Commercial India

Recordati Raises Forecast for Isturisa After Smooth Launches

The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.

Sales & Earnings Rare Diseases

Sun Loses Shine In Q1, Testing Times In US

Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.

Commercial Strategy

Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales

The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus. 

Sales & Earnings Coronavirus COVID-19

AbbVie Says Botox Business Recovering But Allergan Drags Down Q2 Financials

AbbVie reported revenue growth during the second quarter, with products like Rinvoq and Skyrizi leading the charge. But Allergan, despite growth for Vraylar and Ubrelvy, pushed down overall performance.

Sales & Earnings Business Strategies

Novo Nordisk Q2 Preview: Focus On Rybelsus, Ozempic And Payors

Novo Nordisk’s 6 August Q2 update will be scrutinized for clues on its plans for semaglutide in obesity, sales data for diabetes drugs Rybelsus and Ozempic, and likely M&A.

Clinical Trials M & A
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Sanofi/GSK Working With The US To Increase COVID-19 Vaccine Capacity

The $2.1bn investment under the US’ Operation Warp Speed will fund development, scale-up of US manufacturing and the first 100 million doses. 

Coronavirus COVID-19 Vaccines

Novartis's Piqray Gets Europe Green Light At Last

It has taken a while but European regulators have finally followed their US counterparts and approved Piqray, making it the first targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation.

Approvals Cancer

India’s Bulk Drugs Incentive Scheme Finds Takers In Mankind, Aarti

As India revealed finer details of two schemes to promote bulk drug production, Mankind Pharma and Aarti Drugs spelled out a preference for chemical synthesis products - they are likely to be joined by more companies reluctant to invest in some that are fermentation-based. Whether a “plug and play” format for bulk drug parks will attract foreign investment remains to be seen.

Policy & Regulation Manufacturing
See All

Research & Development Explore this Topic

Set Alert for Research & Development

Pipeline Watch: Phase III Starts With AL001, Beremagene Geperpavec And Relacorilant

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Coronavirus Update: Russia Plans First Vaccinations In October

Concern and skepticism about Russia's rapid vaccine roll out. Meanwhile Japan is latest to reach deal with Pfizer/BioNTech.

Coronavirus COVID-19 Vaccines

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Coronavirus COVID-19 Research & Development
See All
UsernamePublicRestriction

Register